Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 1-Year Low - Time to Sell?

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) reached a new 52-week low on Tuesday . The company traded as low as $16.67 and last traded at $16.69, with a volume of 381730 shares trading hands. The stock had previously closed at $17.71.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on ARWR shares. B. Riley reissued a "buy" rating and issued a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Chardan Capital restated a "buy" rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Royal Bank of Canada restated an "outperform" rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. HC Wainwright restated a "buy" rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. Finally, StockNews.com upgraded Arrowhead Pharmaceuticals to a "sell" rating in a research report on Friday, December 20th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $41.44.

Arrowhead Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. The firm's 50-day moving average is $19.46 and its two-hundred day moving average is $20.60. The company has a market cap of $2.23 billion, a P/E ratio of -3.42 and a beta of 0.95.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.97). Analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Insider Activity

In related news, CEO Christopher Richard Anzalone sold 133,333 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $17.02, for a total transaction of $2,269,327.66. Following the completion of the transaction, the chief executive officer now directly owns 3,773,802 shares of the company's stock, valued at approximately $64,230,110.04. The trade was a 3.41 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Adeoye Y. Olukotun sold 2,850 shares of the stock in a transaction dated Friday, December 27th. The stock was sold at an average price of $20.00, for a total transaction of $57,000.00. Following the completion of the sale, the director now directly owns 36,740 shares in the company, valued at $734,800. This trade represents a 7.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 280,765 shares of company stock valued at $5,227,313 in the last ninety days. Insiders own 4.30% of the company's stock.

Institutional Trading of Arrowhead Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of ARWR. R Squared Ltd bought a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter worth about $38,000. GF Fund Management CO. LTD. purchased a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth approximately $49,000. Van ECK Associates Corp increased its position in shares of Arrowhead Pharmaceuticals by 72.3% during the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock worth $56,000 after acquiring an additional 1,250 shares during the period. KBC Group NV raised its stake in shares of Arrowhead Pharmaceuticals by 45.9% during the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock valued at $98,000 after acquiring an additional 1,644 shares in the last quarter. Finally, Mackenzie Financial Corp purchased a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $137,000. Hedge funds and other institutional investors own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.